BioSpace News Archive

Between 12 and 20 percent of Americans over age 60 have peripheral arterial disease.

Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company’s plans for its previously disclosed dividend distribution.

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that five patients who participated in the STEM trial (“STEM”) received SFX-01 treatment for over one year, with two of these five patients continuing to be treated with SFX-01.

Stanford Children’s Health announced that it has achieved Magnet recognition as a reflection of its exemplary professional nursing practice, interprofessional teamwork and preeminent patient care.

4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant Technology™ announced today the completion of Phase I in vitro testing that demonstrates the surface roughness on its truss implants stimulates a superior osteogenic response when compared to smooth titanium and PEEK.

Gossamer Bio, Inc. announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2 at 7:45 a.m. ET.

Tetraphase Pharmaceuticals, Inc. announced that data on XERAVA will be featured in seven poster presentations at the Infectious Disease Society of America’s (IDSA) Infectious Disease Week (IDWeek) 2019, taking place October 2-6 in Washington, DC, at the Walter E. Washington Convention Center.

The Medicines Company announced positive topline results for the ORION-10 Phase 3 clinical study in patients with atherosclerotic cardiovascular disease, successfully completing the pivotal Phase 3 LDL-cholesterol lowering clinical trials for inclisiran.

The National Resident Matching Program® (NRMP®) is pleased to announce that its national stakeholder conference, Transition to Residency: Conversations Across the Medical Education Continuum, will take place October 3-5, 2019 at the Westin Michigan Avenue in Chicago.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will deliver a corporate presentation at the 2019 Cantor Global Healthcare Conference, being held October 2-4, 2019 in New York, NY.